{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:56:23Z","timestamp":1790898983688,"version":"4.1.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-0452; W81XWH-22-1-0913"],"award-info":[{"award-number":["HT9425-23-1-0452; W81XWH-22-1-0913"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01368-3","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:54:54Z","timestamp":1773500094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genomic landscape and precision therapy in prostate cancer: current status and future directions"],"prefix":"10.1038","volume":"10","author":[{"given":"John A.","family":"Ligon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawed A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Clark","family":"Henegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"1368_CR1","doi-asserted-by":"crossref","unstructured":"Kratzer, T. B. et al. Prostate cancer statistics, 2025. CA Cancer J Clin, 2025.","DOI":"10.3322\/caac.70028"},{"key":"1368_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L. et al. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"1368_CR3","doi-asserted-by":"publisher","first-page":"1467540","DOI":"10.3389\/fonc.2025.1467540","volume":"15","author":"F Wu","year":"2025","unstructured":"Wu, F., Zhang, H. & Hao, M. Interactions between key genes and pathways in prostate cancer progression and therapy resistance. Front. Oncol. 15, 1467540 (2025).","journal-title":"Front. Oncol."},{"key":"1368_CR4","doi-asserted-by":"publisher","first-page":"1530580","DOI":"10.3389\/fonc.2025.1530580","volume":"15","author":"DMC Poon","year":"2025","unstructured":"Poon, D. M. C. et al. Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy. Front. Oncol. 15, 1530580 (2025).","journal-title":"Front. Oncol."},{"key":"1368_CR5","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/ng.3930","volume":"49","author":"KJ Kron","year":"2017","unstructured":"Kron, K. J. et al. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat. Genet. 49, 1336\u20131345 (2017).","journal-title":"Nat. Genet."},{"key":"1368_CR6","doi-asserted-by":"publisher","first-page":"e86824","DOI":"10.1371\/journal.pone.0086824","volume":"9","author":"C Hagglof","year":"2014","unstructured":"Hagglof, C. et al. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS One 9, e86824 (2014).","journal-title":"PLoS One"},{"key":"1368_CR7","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1038\/s41388-018-0409-7","volume":"37","author":"Z Xu","year":"2018","unstructured":"Xu, Z. et al. Nuclear receptor ERRalpha and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer. Oncogene 37, 6259\u20136274 (2018).","journal-title":"Oncogene"},{"key":"1368_CR8","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1038\/onc.2013.176","volume":"33","author":"TV Tian","year":"2014","unstructured":"Tian, T. V. et al. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene 33, 2204\u20132214 (2014).","journal-title":"Oncogene"},{"key":"1368_CR9","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1158\/0008-5472.CAN-20-2044","volume":"80","author":"N Shah","year":"2020","unstructured":"Shah, N. et al. ERG-mediated coregulator complex formation maintains androgen receptor signaling in prostate cancer. Cancer Res. 80, 4612\u20134619 (2020).","journal-title":"Cancer Res."},{"key":"1368_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/modpathol.3800769","volume":"20","author":"R Mehra","year":"2007","unstructured":"Mehra, R. et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 20, 538\u2013544 (2007).","journal-title":"Mod. Pathol."},{"key":"1368_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nrc2402","volume":"8","author":"C Kumar-Sinha","year":"2008","unstructured":"Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 8, 497\u2013511 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"1368_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644\u2013648 (2005).","journal-title":"Science"},{"key":"1368_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.2279","volume":"44","author":"CE Barbieri","year":"2012","unstructured":"Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685\u2013689 (2012).","journal-title":"Nat. Genet."},{"key":"1368_CR14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/pros.24218","volume":"81","author":"S Hernandez-Llodra","year":"2021","unstructured":"Hernandez-Llodra, S. et al. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence. Prostate 81, 1267\u20131277 (2021).","journal-title":"Prostate"},{"key":"1368_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-22-2801","volume":"83","author":"H Zhang","year":"2023","unstructured":"Zhang, H., Jin, X. & Huang, H. Deregulation of SPOP in Cancer. Cancer Res. 83, 489\u2013499 (2023).","journal-title":"Cancer Res."},{"key":"1368_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ccell.2017.02.004","volume":"31","author":"M Blattner","year":"2017","unstructured":"Blattner, M. et al. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K\/mTOR and AR Signaling. Cancer Cell 31, 436\u2013451 (2017).","journal-title":"Cancer Cell"},{"key":"1368_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4972","volume":"5","author":"HJ Jin","year":"2014","unstructured":"Jin, H. J. et al. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat. Commun. 5, 3972 (2014).","journal-title":"Nat. Commun."},{"key":"1368_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57854-w","volume":"14","author":"KJ Tam","year":"2024","unstructured":"Tam, K. J. et al. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. Sci. Rep. 14, 7082 (2024).","journal-title":"Sci. Rep."},{"key":"1368_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.15252\/emmm.201707689","volume":"10","author":"JW Peacock","year":"2018","unstructured":"Peacock, J. W. et al. SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol. Med. 10, 219\u2013238 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1368_CR20","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/pros.23830","volume":"79","author":"S Hernandez-Llodra","year":"2019","unstructured":"Hernandez-Llodra, S. et al. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer. Prostate 79, 1156\u20131165 (2019).","journal-title":"Prostate"},{"key":"1368_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","volume":"571","author":"A Parolia","year":"2019","unstructured":"Parolia, A. et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature 571, 413\u2013418 (2019).","journal-title":"Nature"},{"key":"1368_CR22","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.clgc.2024.102226","volume":"22","author":"MM Maddah","year":"2024","unstructured":"Maddah, M. M. et al. Evaluation of the Prognostic Role of TP53 Gene Mutations in Prostate Cancer Outcome: A Systematic Review and Meta-Analysis. Clin. Genitourin. Cancer 22, 102226 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1368_CR23","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","volume":"20","author":"HL Tan","year":"2014","unstructured":"Tan, H. L. et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20, 890\u2013903 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1368_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"1368_CR25","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1073\/pnas.95.9.5246","volume":"95","author":"YE Whang","year":"1998","unstructured":"Whang, Y. E. et al. Inactivation of the tumor suppressor PTEN\/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 95, 5246\u20135250 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1368_CR26","doi-asserted-by":"crossref","unstructured":"Pungsrinont, T., Kallenbach, J. & Baniahmad, A. Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int. J. Mol. Sci. 22 (2021).","DOI":"10.3390\/ijms222011088"},{"key":"1368_CR27","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0022-5347(05)65723-0","volume":"166","author":"JM Latini","year":"2001","unstructured":"Latini, J. M. et al. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions. J. Urol. 166, 1931\u20131936 (2001).","journal-title":"J. Urol."},{"key":"1368_CR28","first-page":"204","volume":"58","author":"H Suzuki","year":"1998","unstructured":"Suzuki, H. et al. Interfocal heterogeneity of PTEN\/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58, 204\u2013209 (1998).","journal-title":"Cancer Res."},{"key":"1368_CR29","first-page":"168","volume":"14","author":"AM Antao","year":"2021","unstructured":"Antao, A. M., Ramakrishna, S. & Kim, K. S. The Role of Nkx3.1 in Cancers and Stemness. Int. J. Stem Cells 14, 168\u2013179 (2021).","journal-title":"Int. J. Stem Cells"},{"key":"1368_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.bbrc.2010.06.099","volume":"398","author":"Z Pengju","year":"2010","unstructured":"Pengju, Z. et al. NKX3.1 potentiates TNF-alpha\/CHX-induced apoptosis of prostate cancer cells through increasing caspase-3 expression and its activity. Biochem. Biophys. Res. Commun. 398, 457\u2013461 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1368_CR31","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-14-3387","volume":"75","author":"C Bowen","year":"2015","unstructured":"Bowen, C., Zheng, T. & Gelmann, E. P. NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage. Cancer Res. 75, 2686\u20132698 (2015).","journal-title":"Cancer Res."},{"key":"1368_CR32","doi-asserted-by":"crossref","unstructured":"Sooreshjani, M. A. et al. LIMK2-NKX3.1 engagement promotes castration-resistant prostate cancer. Cancers 13, 2324 (2021).","DOI":"10.3390\/cancers13102324"},{"key":"1368_CR33","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1038\/onc.2011.590","volume":"31","author":"S Huang","year":"2012","unstructured":"Huang, S. et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 31, 4164\u20134170 (2012).","journal-title":"Oncogene"},{"key":"1368_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","volume":"35","author":"MA Augello","year":"2019","unstructured":"Augello, M. A. et al. CHD1 Loss Alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate Tumorigenesis. Cancer Cell 35, 603\u2013617 e8 (2019).","journal-title":"Cancer Cell"},{"key":"1368_CR35","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.15252\/embr.201642352","volume":"17","author":"V Kari","year":"2016","unstructured":"Kari, V. et al. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep. 17, 1609\u20131623 (2016).","journal-title":"EMBO Rep."},{"key":"1368_CR36","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1093\/nar\/gky128","volume":"46","author":"J Zhou","year":"2018","unstructured":"Zhou, J. et al. Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus. Nucleic Acids Res. 46, 3891\u20133905 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1368_CR37","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/annonc\/mdx165","volume":"28","author":"TR Shenoy","year":"2017","unstructured":"Shenoy, T. R. et al. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann. Oncol. 28, 1495\u20131507 (2017).","journal-title":"Ann. Oncol."},{"key":"1368_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1593\/neo.131704","volume":"16","author":"M Blattner","year":"2014","unstructured":"Blattner, M. et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 16, 14\u201320 (2014).","journal-title":"Neoplasia"},{"key":"1368_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/MOU.0000000000000285","volume":"26","author":"SD Kaffenberger","year":"2016","unstructured":"Kaffenberger, S. D. & Barbieri, C. E. Molecular subtyping of prostate cancer. Curr. Opin. Urol. 26, 213\u2013218 (2016).","journal-title":"Curr. Opin. Urol."},{"key":"1368_CR40","first-page":"524","volume":"57","author":"RB Jenkins","year":"1997","unstructured":"Jenkins, R. B. et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57, 524\u2013531 (1997).","journal-title":"Cancer Res."},{"key":"1368_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30257-z","volume":"13","author":"X Qiu","year":"2022","unstructured":"Qiu, X. et al. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat. Commun. 13, 2559 (2022).","journal-title":"Nat. Commun."},{"key":"1368_CR42","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.humpath.2013.01.012","volume":"44","author":"G Fromont","year":"2013","unstructured":"Fromont, G. et al. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. Hum. Pathol. 44, 1617\u20131623 (2013).","journal-title":"Hum. Pathol."},{"key":"1368_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.humpath.2003.10.019","volume":"35","author":"S Bastacky","year":"2004","unstructured":"Bastacky, S. et al. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy. Hum. Pathol. 35, 281\u2013289 (2004).","journal-title":"Hum. Pathol."},{"key":"1368_CR44","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.clgc.2023.10.008","volume":"22","author":"WH Jin","year":"2024","unstructured":"Jin, W. H. et al. The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate Cancer. Clin. Genitourin. Cancer 22, e163\u2013e169.e1 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1368_CR45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","volume":"37","author":"K Fujita","year":"2019","unstructured":"Fujita, K. & Nonomura, N. Role of Androgen Receptor in Prostate Cancer: A Review. World J. Mens. Health 37, 288\u2013295 (2019).","journal-title":"World J. Mens. Health"},{"key":"1368_CR46","first-page":"211","volume":"17","author":"A Quistini","year":"2025","unstructured":"Quistini, A. et al. Androgen Receptor Signalling in Prostate Cancer: Mechanisms of Resistance to Endocrine Therapies. Res. Rep. Urol. 17, 211\u2013223 (2025).","journal-title":"Res. Rep. Urol."},{"key":"1368_CR47","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","volume":"21","author":"AA Azad","year":"2015","unstructured":"Azad, A. A. et al. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin. Cancer Res. 21, 2315\u20132324 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1368_CR48","doi-asserted-by":"publisher","first-page":"217916","DOI":"10.1016\/j.canlet.2025.217916","volume":"631","author":"S Anand","year":"2025","unstructured":"Anand, S. et al. MYB and HIF1alpha crosstalk drives hypoxia-induced transcriptional reprogramming and adaptive signaling alterations in pancreatic cancer. Cancer Lett. 631, 217916 (2025).","journal-title":"Cancer Lett."},{"key":"1368_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10555-023-10153-8","volume":"43","author":"S Anand","year":"2024","unstructured":"Anand, S. et al. From modulation of cellular plasticity to potentiation of therapeutic resistance: new and emerging roles of MYB transcription factors in human malignancies. Cancer Metastas. Rev. 43, 409\u2013421 (2024).","journal-title":"Cancer Metastas. Rev."},{"key":"1368_CR50","first-page":"5271","volume":"9","author":"J Edwards","year":"2003","unstructured":"Edwards, J. et al. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin. Cancer Res. 9, 5271\u20135281 (2003).","journal-title":"Clin. Cancer Res."},{"key":"1368_CR51","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/carcin\/bgs134","volume":"33","author":"SK Srivastava","year":"2012","unstructured":"Srivastava, S. K. et al. Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis 33, 1149\u20131157 (2012).","journal-title":"Carcinogenesis"},{"key":"1368_CR52","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41416-021-01641-1","volume":"126","author":"SK Srivastava","year":"2022","unstructured":"Srivastava, S. K. et al. MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer. Br. J. Cancer 126, 1205\u20131214 (2022).","journal-title":"Br. J. Cancer"},{"key":"1368_CR53","doi-asserted-by":"publisher","first-page":"108487","DOI":"10.1016\/j.isci.2023.108487","volume":"26","author":"MA Khan","year":"2023","unstructured":"Khan, M. A. et al. MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer. iScience 26, 108487 (2023).","journal-title":"iScience"},{"key":"1368_CR54","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-17-3564","volume":"78","author":"X Lu","year":"2018","unstructured":"Lu, X. et al. An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer. Cancer Res. 78, 3823\u20133833 (2018).","journal-title":"Cancer Res."},{"key":"1368_CR55","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1042\/BCJ20160590","volume":"473","author":"PG Andrews","year":"2016","unstructured":"Andrews, P. G. & Kao, K. R. Wnt\/beta-catenin-dependent acetylation of Pygo2 by CBP\/p300 histone acetyltransferase family members. Biochem. J. 473, 4193\u20134203 (2016).","journal-title":"Biochem. J."},{"key":"1368_CR56","doi-asserted-by":"publisher","first-page":"113696","DOI":"10.1016\/j.yexcr.2023.113696","volume":"431","author":"J Ling","year":"2023","unstructured":"Ling, J. et al. Pygo2 activates BRPF1 via Pygo2-H3K4me2\/3 interaction to maintain malignant progression in colon cancer. Exp. Cell Res. 431, 113696 (2023).","journal-title":"Exp. Cell Res."},{"key":"1368_CR57","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.celrep.2018.04.020","volume":"23","author":"PGP Andrews","year":"2018","unstructured":"Andrews, P. G. P. et al. Augmentation of Myc-Dependent Mitotic Gene Expression by the Pygopus2 Chromatin Effector. Cell Rep. 23, 1516\u20131529 (2018).","journal-title":"Cell Rep."},{"key":"1368_CR58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/jclinpath-2017-204718","volume":"71","author":"KR Kao","year":"2018","unstructured":"Kao, K. R. et al. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy. J. Clin. Pathol. 71, 402\u2013411 (2018).","journal-title":"J. Clin. Pathol."},{"key":"1368_CR59","doi-asserted-by":"publisher","first-page":"eade4656","DOI":"10.1126\/sciimmunol.ade4656","volume":"8","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Sci. Immunol. 8, eade4656 (2023).","journal-title":"Sci. Immunol."},{"key":"1368_CR60","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/carcin\/bgv137","volume":"36","author":"N Melling","year":"2015","unstructured":"Melling, N. et al. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Carcinogenesis 36, 1333\u20131340 (2015).","journal-title":"Carcinogenesis"},{"key":"1368_CR61","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eururo.2004.06.014","volume":"46","author":"R Henrique","year":"2004","unstructured":"Henrique, R. & Jeronimo, C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur. Urol. 46, 660\u2013669 (2004). discussion 669.","journal-title":"Eur. Urol."},{"key":"1368_CR62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/pros.23111","volume":"76","author":"OY Mian","year":"2016","unstructured":"Mian, O. Y. et al. GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate 76, 199\u2013206 (2016).","journal-title":"Prostate"},{"key":"1368_CR63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mc.21939","volume":"53","author":"R Kanwal","year":"2014","unstructured":"Kanwal, R. et al. Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1. Mol. Carcinog. 53, 8\u201318 (2014).","journal-title":"Mol. Carcinog."},{"key":"1368_CR64","doi-asserted-by":"publisher","first-page":"559","DOI":"10.4103\/1008-682X.177839","volume":"18","author":"B Kumar","year":"2016","unstructured":"Kumar, B. & Lupold, S. E. MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery. Asian J. Androl. 18, 559\u2013567 (2016).","journal-title":"Asian J. Androl."},{"key":"1368_CR65","doi-asserted-by":"publisher","first-page":"102725","DOI":"10.1016\/j.jbc.2022.102725","volume":"299","author":"S Acharya","year":"2023","unstructured":"Acharya, S. et al. Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer. J. Biol. Chem. 299, 102725 (2023).","journal-title":"J. Biol. Chem."},{"key":"1368_CR66","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3233\/NPM-15814099","volume":"8","author":"P Holtrop","year":"2015","unstructured":"Holtrop, P., Swails, T. & Riggs, T. Hypertriglyceridemia in extremely low birth weight infants receiving lipid emulsions. J. Neonatal Perinat. Med. 8, 133\u2013136 (2015).","journal-title":"J. Neonatal Perinat. Med."},{"key":"1368_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25320-z","volume":"8","author":"B Kumar","year":"2018","unstructured":"Kumar, B. et al. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci. Rep. 8, 7189 (2018).","journal-title":"Sci. Rep."},{"key":"1368_CR68","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1530\/ERC-16-0525","volume":"24","author":"B Smith","year":"2017","unstructured":"Smith, B., Agarwal, P. & Bhowmick, N. A. MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. Endocr. Relat. Cancer 24, R157\u2013R172 (2017).","journal-title":"Endocr. Relat. Cancer"},{"key":"1368_CR69","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00018-016-2176-3","volume":"73","author":"V Doldi","year":"2016","unstructured":"Doldi, V. et al. Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches. Cell Mol. Life Sci. 73, 2531\u20132542 (2016).","journal-title":"Cell Mol. Life Sci."},{"key":"1368_CR70","doi-asserted-by":"crossref","unstructured":"Zenner, M. L. et al. Prostate-derived circulating microRNAs add prognostic value to prostate cancer risk calculators. J. Extracell. Biol. 2, e122 (2023).","DOI":"10.1002\/jex2.122"},{"key":"1368_CR71","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-24-1388","volume":"84","author":"KE Rodarte","year":"2024","unstructured":"Rodarte, K. E. et al. Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1. Cancer Res. 84, 3522\u20133537 (2024).","journal-title":"Cancer Res."},{"key":"1368_CR72","doi-asserted-by":"publisher","first-page":"12372","DOI":"10.18632\/oncotarget.6029","volume":"7","author":"MV Russo","year":"2016","unstructured":"Russo, M. V. et al. SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis. Oncotarget 7, 12372\u201312385 (2016).","journal-title":"Oncotarget"},{"key":"1368_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49234-9","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. Nat. Commun. 15, 4914 (2024).","journal-title":"Nat. Commun."},{"key":"1368_CR74","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","volume":"24","author":"M Rotinen","year":"2018","unstructured":"Rotinen, M. et al. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat. Med. 24, 1887\u20131898 (2018).","journal-title":"Nat. Med."},{"key":"1368_CR75","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop, J. L. et al. The Master Neural Transcription Factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54\u201371 (2017).","journal-title":"Cancer Discov."},{"key":"1368_CR76","doi-asserted-by":"crossref","unstructured":"Imamura, J. et al. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution. Front. Endocrinol. 14, 1191311 (2023).","DOI":"10.3389\/fendo.2023.1191311"},{"key":"1368_CR77","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne, E. et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell 30, 563\u2013577 (2016).","journal-title":"Cancer Cell"},{"key":"1368_CR78","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1158\/1078-0432.CCR-19-0317","volume":"25","author":"B Liu","year":"2019","unstructured":"Liu, B. et al. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin. Cancer Res. 25, 6839\u20136851 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1368_CR79","doi-asserted-by":"crossref","unstructured":"Maylin, Z. R. et al. Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer. Cells 13, 1999 (2024).","DOI":"10.3390\/cells13231999"},{"key":"1368_CR80","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 5, 471\u2013478 (2019).","journal-title":"JAMA Oncol."},{"key":"1368_CR81","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.eururo.2024.04.026","volume":"86","author":"N Klumper","year":"2024","unstructured":"Klumper, N. et al. The Role of Microsatellite Instability\/DNA mismatch repair deficiency and tumor mutational burden as biomarkers in predicting response to immunotherapy in castration-resistant prostate cancer. Eur. Urol. 86, 388\u2013390 (2024).","journal-title":"Eur. Urol."},{"key":"1368_CR82","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","volume":"30","author":"AT Lenis","year":"2024","unstructured":"Lenis, A. T. et al. Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clin. Cancer Res. 30, 3894\u20133903 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1368_CR83","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo, J. et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N. Engl. J. Med. 373, 1697\u20131708 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1368_CR84","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","volume":"4","author":"Q Karlsson","year":"2021","unstructured":"Karlsson, Q. et al. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. Eur. Urol. Oncol. 4, 570\u2013579 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1368_CR85","doi-asserted-by":"crossref","unstructured":"Stolarova, L. et al. CHEK2 germline variants in cancer predisposition: stalemate rather than checkmate. Cells 9, 2675 (2020).","DOI":"10.3390\/cells9122675"},{"key":"1368_CR86","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","volume":"126","author":"T Nyberg","year":"2022","unstructured":"Nyberg, T., Tischkowitz, M. & Antoniou, A. C. BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis. Br. J. Cancer 126, 1067\u20131081 (2022).","journal-title":"Br. J. Cancer"},{"key":"1368_CR87","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/pros.24123","volume":"81","author":"EM Ledet","year":"2021","unstructured":"Ledet, E. M. et al. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate 81, 433\u2013439 (2021).","journal-title":"Prostate"},{"key":"1368_CR88","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","volume":"77","author":"T Nyberg","year":"2020","unstructured":"Nyberg, T. et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur. Urol. 77, 24\u201335 (2020).","journal-title":"Eur. Urol."},{"key":"1368_CR89","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/1078-0432.CCR-08-1822","volume":"15","author":"I Agalliu","year":"2009","unstructured":"Agalliu, I. et al. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin. Cancer Res. 15, 1112\u20131120 (2009).","journal-title":"Clin. Cancer Res."},{"key":"1368_CR90","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/pros.23795","volume":"79","author":"M Oh","year":"2019","unstructured":"Oh, M. et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate 79, 880\u2013895 (2019).","journal-title":"Prostate"},{"key":"1368_CR91","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2018.11.015","volume":"75","author":"T Nyberg","year":"2019","unstructured":"Nyberg, T. et al. Homeobox B13 G84E Mutation and Prostate Cancer Risk. Eur. Urol. 75, 834\u2013845 (2019).","journal-title":"Eur. Urol."},{"key":"1368_CR92","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1110000","volume":"366","author":"CM Ewing","year":"2012","unstructured":"Ewing, C. M. et al. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl. J. Med. 366, 141\u2013149 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1368_CR93","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.eururo.2012.07.027","volume":"65","author":"R Karlsson","year":"2014","unstructured":"Karlsson, R. et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur. Urol. 65, 169\u2013176 (2014).","journal-title":"Eur. Urol."},{"key":"1368_CR94","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jnci\/djaa132","volume":"113","author":"BF Darst","year":"2021","unstructured":"Darst, B. F. et al. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. J. Natl. Cancer Inst. 113, 616\u2013625 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"1368_CR95","doi-asserted-by":"publisher","first-page":"104773","DOI":"10.1016\/j.cellimm.2023.104773","volume":"393-394","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. ATM-AMPKalpha mediated LAG-3 expression suppresses T cell function in prostate cancer. Cell Immunol. 393-394, 104773 (2023).","journal-title":"Cell Immunol."},{"key":"1368_CR96","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/pros.23505","volume":"78","author":"Y Wu","year":"2018","unstructured":"Wu, Y. et al. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. Prostate 78, 607\u2013615 (2018).","journal-title":"Prostate"},{"key":"1368_CR97","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1158\/0008-5472.CAN-04-0341","volume":"64","author":"C Cybulski","year":"2004","unstructured":"Cybulski, C. et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res. 64, 2677\u20132679 (2004).","journal-title":"Cancer Res."},{"key":"1368_CR98","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N. Engl. J. Med. 375, 443\u2013453 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1368_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07927-y","volume":"10","author":"AM Heijink","year":"2019","unstructured":"Heijink, A. M. et al. BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity. Nat. Commun. 10, 100 (2019).","journal-title":"Nat. Commun."},{"key":"1368_CR100","doi-asserted-by":"crossref","unstructured":"Hu, M. et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation. J. Clin. Invest. 131, e139333 (2021).","DOI":"10.1172\/JCI139333"},{"key":"1368_CR101","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/2159-8290.CD-19-1352","volume":"10","author":"D Zhao","year":"2020","unstructured":"Zhao, D. et al. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov. 10, 1374\u20131387 (2020).","journal-title":"Cancer Discov."},{"key":"1368_CR102","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/pros.23808","volume":"79","author":"T Vidotto","year":"2019","unstructured":"Vidotto, T. et al. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. Prostate 79, 969\u2013979 (2019).","journal-title":"Prostate"},{"key":"1368_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51450-2","volume":"15","author":"MK Graham","year":"2024","unstructured":"Graham, M. K. et al. Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. Nat. Commun. 15, 7414 (2024).","journal-title":"Nat. Commun."},{"key":"1368_CR104","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227\u2013231 (2016).","journal-title":"Science"},{"key":"1368_CR105","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2159-8290.CD-24-0559","volume":"15","author":"LN Chesner","year":"2025","unstructured":"Chesner, L. N. et al. Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer. Cancer Discov. 15, 481\u2013494 (2025).","journal-title":"Cancer Discov."},{"key":"1368_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206889","volume":"10","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. IL-1beta Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer. Adv. Sci. 10, e2206889 (2023).","journal-title":"Adv. Sci."},{"key":"1368_CR107","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/2767-9764.CRC-25-0409","volume":"6","author":"YM Hu","year":"2026","unstructured":"Hu, Y. M. et al. Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types. Cancer Res Commun. 6, 17\u201335 (2026).","journal-title":"Cancer Res Commun."},{"key":"1368_CR108","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","volume":"29","author":"B Bhinder","year":"2023","unstructured":"Bhinder, B. et al. Immunogenomic Landscape of Neuroendocrine Prostate Cancer. Clin. Cancer Res 29, 2933\u20132943 (2023).","journal-title":"Clin. Cancer Res"},{"key":"1368_CR109","doi-asserted-by":"crossref","unstructured":"Li, S. et al. Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer. bioRxivp, (2025).","DOI":"10.1101\/2025.02.12.637904"},{"key":"1368_CR110","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/1541-7786.MCR-18-0837","volume":"17","author":"K Zennami","year":"2019","unstructured":"Zennami, K. et al. PDCD4 Is an androgen-repressed tumor suppressor that regulates prostate cancer growth and castration resistance. Mol. Cancer Res. 17, 618\u2013627 (2019).","journal-title":"Mol. Cancer Res."},{"key":"1368_CR111","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/s41388-018-0178-3","volume":"37","author":"J Xi","year":"2018","unstructured":"Xi, J. et al. miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. Oncogene 37, 3151\u20133165 (2018).","journal-title":"Oncogene"},{"key":"1368_CR112","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1038\/onc.2013.230","volume":"33","author":"T Sun","year":"2014","unstructured":"Sun, T. et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 33, 2790\u20132800 (2014).","journal-title":"Oncogene"},{"key":"1368_CR113","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-020-01570-6","volume":"39","author":"S Tan","year":"2020","unstructured":"Tan, S. et al. Exosomal miRNAs in tumor microenvironment. J. Exp. Clin. Cancer Res. 39, 67 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1368_CR114","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO-24-02608","volume":"43","author":"EY Yu","year":"2025","unstructured":"Yu, E. Y. et al. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J. Clin. Oncol. 43, 748\u2013758 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1368_CR115","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028\u20131038 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1368_CR116","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher, H. I. et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2, 1441\u20131449 (2016).","journal-title":"JAMA Oncol."},{"key":"1368_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2019.09.015","volume":"18","author":"T Zhang","year":"2020","unstructured":"Zhang, T. et al. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. Clin. Genitourin. Cancer 18, 1\u201310 (2020).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1368_CR118","doi-asserted-by":"crossref","unstructured":"Hille, C. et al. Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer. Cells. 8, 1067 (2019).","DOI":"10.3390\/cells8091067"},{"key":"1368_CR119","doi-asserted-by":"publisher","first-page":"107669","DOI":"10.1016\/j.celrep.2020.107669","volume":"31","author":"MD Nyquist","year":"2020","unstructured":"Nyquist, M. D. et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 31, 107669 (2020).","journal-title":"Cell Rep."},{"key":"1368_CR120","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili, T. et al. Clinical implications of PTEN loss in prostate cancer. Nat. Rev. Urol. 15, 222\u2013234 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"1368_CR121","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/1878-0261.13641","volume":"18","author":"S Yoshida","year":"2024","unstructured":"Yoshida, S. et al. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer. Mol. Oncol. 18, 1980\u20132000 (2024).","journal-title":"Mol. Oncol."},{"key":"1368_CR122","doi-asserted-by":"publisher","first-page":"175883592312213","DOI":"10.1177\/17588359231221337","volume":"16","author":"MT Bourlon","year":"2024","unstructured":"Bourlon, M. T., Valdez, P. & Castro, E. Development of PARP inhibitors in advanced prostate cancer. Ther. Adv. Med. Oncol. 16, 17588359231221337 (2024).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1368_CR123","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1368_CR124","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","volume":"84","author":"W Abida","year":"2023","unstructured":"Abida, W. et al. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur. Urol. 84, 321\u2013330 (2023).","journal-title":"Eur. Urol."},{"key":"1368_CR125","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke, N. W. et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 1, EVIDoa2200043 (2022).","journal-title":"NEJM Evid."},{"key":"1368_CR126","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","volume":"406","author":"N Agarwal","year":"2025","unstructured":"Agarwal, N. et al. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet 406, 447\u2013460 (2025).","journal-title":"Lancet"},{"key":"1368_CR127","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","volume":"30","author":"M Hussain","year":"2024","unstructured":"Hussain, M. et al. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin. Cancer Res. 30, 4318\u20134328 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1368_CR128","doi-asserted-by":"crossref","unstructured":"Attard, G. et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat. Med. 31, 4109\u20134118 (2025).","DOI":"10.1038\/s41591-025-03961-8"},{"key":"1368_CR129","doi-asserted-by":"crossref","unstructured":"Fizazi, K. et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study. Ann. Oncol. 37, 53\u201368 (2026).","DOI":"10.1016\/j.annonc.2025.12.007"},{"key":"1368_CR130","doi-asserted-by":"publisher","first-page":"114103","DOI":"10.1016\/j.ejca.2024.114103","volume":"205","author":"P Rescigno","year":"2024","unstructured":"Rescigno, P. et al. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. Eur. J. Cancer 205, 114103 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1368_CR131","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.20.01576","volume":"39","author":"SJ Crabb","year":"2021","unstructured":"Crabb, S. J. et al. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID). J. Clin. Oncol. 39, 190\u2013201 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1368_CR132","unstructured":"AstraZeneca, TRUQAP\u00ae (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial. AstraZeneca Media. (2024)."},{"key":"1368_CR133","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney, C. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398, 131\u2013142 (2021).","journal-title":"Lancet"},{"key":"1368_CR134","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","volume":"87","author":"JS de Bono","year":"2025","unstructured":"de Bono, J. S. et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur. Urol. 87, 672\u2013682 (2025).","journal-title":"Eur. Urol."},{"key":"1368_CR135","doi-asserted-by":"crossref","unstructured":"Michael Thomas Schweizer, K.P., Atish Dipankar Choudhury, Emiliano Calvo, Richard C. Frank, Li Liu, Rajendar K. Mittapalli, Jessica Tougias, Claudia Andreu-Vieyra, Timothy Geoffrey Bowler, Neelesh Soman, and Benjamin Garmezy, Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC). in 2024 ASCO Annual MeetingJ. Clin. Oncol. (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.5061"},{"key":"1368_CR136","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","volume":"31","author":"R Aggarwal","year":"2025","unstructured":"Aggarwal, R. et al. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clin. Cancer Res. 31, 3854\u20133863 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1368_CR137","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff, T. B. et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 30, 1636\u20131644 (2024).","journal-title":"Nat. Med."},{"key":"1368_CR138","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"1368_CR139","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","volume":"186","author":"DT Le","year":"2023","unstructured":"Le, D. T. et al. Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur. J. Cancer 186, 185\u2013195 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1368_CR140","doi-asserted-by":"publisher","first-page":"e0233260","DOI":"10.1371\/journal.pone.0233260","volume":"15","author":"LS Graham","year":"2020","unstructured":"Graham, L. S. et al. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. PLoS One 15, e0233260 (2020).","journal-title":"PLoS One"},{"key":"1368_CR141","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"YM Wu","year":"2018","unstructured":"Wu, Y. M. et al. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173, 1770\u20131782.e14 (2018).","journal-title":"Cell"},{"key":"1368_CR142","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cancergen.2025.06.002","volume":"296-297","author":"K Higa","year":"2025","unstructured":"Higa, K. et al. Efficacy of pembrolizumab in MSI-high and BRCA-positive castration-resistant prostate cancer. Cancer Genet. 296-297, 41\u201344 (2025).","journal-title":"Cancer Genet."},{"key":"1368_CR143","doi-asserted-by":"crossref","unstructured":"Peyraud, F. & Italiano, A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers 12, 1502 (2020).","DOI":"10.3390\/cancers12061502"},{"key":"1368_CR144","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.euo.2025.04.025","volume":"8","author":"P Rescigno","year":"2025","unstructured":"Rescigno, P. et al. PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes. Eur. Urol. Oncol. 8, 1059\u20131069 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1368_CR145","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma, P. et al. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell 38, 489\u2013499.e3 (2020).","journal-title":"Cancer Cell"},{"key":"1368_CR146","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1200\/JCO-24-02637","volume":"43","author":"G Leone","year":"2025","unstructured":"Leone, G. et al. Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study. J. Clin. Oncol. 43, 3070\u20133080 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1368_CR147","doi-asserted-by":"crossref","unstructured":"You, G. et al. B7-H3x4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes. Sci. Adv. 7, eaax3160 (2021).","DOI":"10.1126\/sciadv.aax3160"},{"key":"1368_CR148","doi-asserted-by":"crossref","unstructured":"Aggarwal, C. et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial. J. Immunother. Cancer 10, e004424 (2022).","DOI":"10.1136\/jitc-2021-004424"},{"key":"1368_CR149","doi-asserted-by":"publisher","first-page":"eadf6724","DOI":"10.1126\/scitranslmed.adf6724","volume":"15","author":"W Shi","year":"2023","unstructured":"Shi, W. et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci. Transl. Med. 15, eadf6724 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1368_CR150","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1368_CR151","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah, J. et al. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin. Cancer Res 29, 1651\u20131657 (2023).","journal-title":"Clin. Cancer Res"},{"key":"1368_CR152","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41585-025-01014-w","volume":"22","author":"C Boixareu","year":"2025","unstructured":"Boixareu, C. et al. Targeting the tumour cell surface in advanced prostate cancer. Nat. Rev. Urol. 22, 569\u2013589 (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1368_CR153","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02489-2","volume":"24","author":"B Chen","year":"2025","unstructured":"Chen, B. et al. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol. Cancer 24, 279 (2025).","journal-title":"Mol. Cancer"},{"key":"1368_CR154","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano, F. et al. Bystander effect of antibody-drug conjugates: fact or fiction? Curr. Oncol. Rep. 24, 809\u2013817 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"1368_CR155","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/pros.23765","volume":"79","author":"DP Petrylak","year":"2019","unstructured":"Petrylak, D. P. et al. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. Prostate 79, 604\u2013613 (2019).","journal-title":"Prostate"},{"key":"1368_CR156","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/pros.23922","volume":"80","author":"DP Petrylak","year":"2020","unstructured":"Petrylak, D. P. et al. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Prostate 80, 99\u2013108 (2020).","journal-title":"Prostate"},{"key":"1368_CR157","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2967\/jnumed.118.222844","volume":"60","author":"JA Carrasquillo","year":"2019","unstructured":"Carrasquillo, J. A. et al. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using (89)Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. J. Nucl. Med 60, 1517\u20131523 (2019).","journal-title":"J. Nucl. Med"},{"key":"1368_CR158","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.19.00646","volume":"37","author":"DC Danila","year":"2019","unstructured":"Danila, D. C. et al. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. J. Clin. Oncol. 37, 3518\u20133527 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1368_CR159","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann. Oncol. 32, 746\u2013756 (2021).","journal-title":"Ann. Oncol."},{"key":"1368_CR160","first-page":"e34490","volume":"15","author":"M Sardinha","year":"2023","unstructured":"Sardinha, M. et al. Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review. Cureus 15, e34490 (2023).","journal-title":"Cureus"},{"key":"1368_CR161","doi-asserted-by":"publisher","first-page":"S744","DOI":"10.1016\/j.annonc.2022.07.582","volume":"33","author":"T Doi","year":"2022","unstructured":"Doi, T. et al. 453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I\/II study. Ann. Oncol. 33, S744\u2013S745 (2022).","journal-title":"Ann. Oncol."},{"key":"1368_CR162","doi-asserted-by":"publisher","first-page":"S996","DOI":"10.1016\/j.annonc.2024.08.1735","volume":"35","author":"JS de Bono","year":"2024","unstructured":"de Bono, J. S. et al. 1654P TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol. 35, S996\u2013S997 (2024).","journal-title":"Ann. Oncol."},{"key":"1368_CR163","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","volume":"20","author":"PG Corn","year":"2019","unstructured":"Corn, P. G. et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 20, 1432\u20131443 (2019).","journal-title":"Lancet Oncol."},{"key":"1368_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li, H. et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol. Cancer 19, 107 (2020).","journal-title":"Mol. Cancer"},{"key":"1368_CR165","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin, K. K. et al. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov. 9, 210\u2013219 (2019).","journal-title":"Cancer Discov."},{"key":"1368_CR166","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1038\/s41388-025-03343-x","volume":"44","author":"M Hofstad","year":"2025","unstructured":"Hofstad, M. et al. Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer. Oncogene 44, 1746\u20131760 (2025).","journal-title":"Oncogene"},{"key":"1368_CR167","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","volume":"80","author":"S Rafiei","year":"2020","unstructured":"Rafiei, S. et al. ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 80, 2094\u20132100 (2020).","journal-title":"Cancer Res."},{"key":"1368_CR168","doi-asserted-by":"publisher","first-page":"e2400254","DOI":"10.1200\/PO.24.00254","volume":"8","author":"M Fatteh","year":"2024","unstructured":"Fatteh, M. et al. Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion. JCO Precis. Oncol. 8, e2400254 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1368_CR169","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","volume":"35","author":"E Harvey-Jones","year":"2024","unstructured":"Harvey-Jones, E. et al. Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Ann. Oncol. 35, 364\u2013380 (2024).","journal-title":"Ann. Oncol."},{"key":"1368_CR170","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/pros.24549","volume":"83","author":"T Derlin","year":"2023","unstructured":"Derlin, T. et al. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. Prostate 83, 1076\u20131088 (2023).","journal-title":"Prostate"},{"key":"1368_CR171","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1078-0432.CCR-19-1485","volume":"26","author":"K Current","year":"2020","unstructured":"Current, K. et al. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity. Clin. Cancer Res. 26, 2946\u20132955 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1368_CR172","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht, M. K. & Beltran, H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat. Rev. Urol. 22, 26\u201345 (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1368_CR173","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran, H. et al. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin. Cancer Res 25, 6916\u20136924 (2019).","journal-title":"Clin. Cancer Res"},{"key":"1368_CR174","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","volume":"2","author":"SP Thang","year":"2019","unstructured":"Thang, S. P. et al. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for (177)Lu-labelled PSMA Radioligand Therapy. Eur. Urol. Oncol. 2, 670\u2013676 (2019).","journal-title":"Eur. Urol. Oncol."},{"key":"1368_CR175","doi-asserted-by":"crossref","unstructured":"Beshiri, M. et al. Prostate organoids: emerging experimental tools for translational research. J. Clin. Invest.133, e169616 (2023).","DOI":"10.1172\/JCI169616"},{"key":"1368_CR176","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ucl.2023.06.006","volume":"51","author":"EY Wong","year":"2024","unstructured":"Wong, E. Y., Chu, T. N. & Ladi-Seyedian, S. S. Genomics and Artificial Intelligence: Prostate Cancer. Urol. Clin. North Am. 51, 27\u201333 (2024).","journal-title":"Urol. Clin. North Am."},{"key":"1368_CR177","doi-asserted-by":"crossref","unstructured":"Yan, L., Su, P. & Sun, X. Role of multi\u2011omics in advancing the understanding and treatment of prostate cancer (Review). Mol. Med. Rep. 31, 130 (2025).","DOI":"10.3892\/mmr.2025.13495"},{"key":"1368_CR178","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s11658-023-00450-z","volume":"28","author":"X Yu","year":"2023","unstructured":"Yu, X. et al. Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment. Cell Mol. Biol. Lett. 28, 38 (2023).","journal-title":"Cell Mol. Biol. Lett."},{"key":"1368_CR179","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1158\/1541-7786.MCR-24-0791","volume":"23","author":"S Mei","year":"2025","unstructured":"Mei, S. et al. Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasis. Mol. Cancer Res. 23, 653\u2013665 (2025).","journal-title":"Mol. Cancer Res."},{"key":"1368_CR180","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01863-2","volume":"22","author":"S Figiel","year":"2023","unstructured":"Figiel, S. et al. Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures. Mol. Cancer 22, 162 (2023).","journal-title":"Mol. Cancer"},{"key":"1368_CR181","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.eururo.2020.12.037","volume":"79","author":"I Casanova-Salas","year":"2021","unstructured":"Casanova-Salas, I. et al. Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer. Eur. Urol. 79, 762\u2013771 (2021).","journal-title":"Eur. Urol."},{"key":"1368_CR182","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.ircmb.2023.06.002","volume":"383","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications. Int Rev. Cell Mol. Biol. 383, 41\u201366 (2024).","journal-title":"Int Rev. Cell Mol. Biol."},{"key":"1368_CR183","doi-asserted-by":"crossref","unstructured":"Bevere, M. et al. An overview of circulating biomarkers in neuroendocrine neoplasms: a clinical guide. Diagnostics 13, 2820 (2023).","DOI":"10.3390\/diagnostics13172820"},{"key":"1368_CR184","unstructured":"Zhao, S. G. et al. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. J. Clin. Invest. 132, e161858 (2022)."},{"key":"1368_CR185","doi-asserted-by":"crossref","unstructured":"Crocetto, F. et al. Liquid biopsy in prostate cancer management-current challenges and future perspectives. Cancers 14, 3272 (2022).","DOI":"10.3390\/cancers14133272"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01368-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01368-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01368-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:02:53Z","timestamp":1777633373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01368-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":185,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1368"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01368-3","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}